Two-Year Clinical Outcomes with Paclitaxel-Eluting Coronary Stents in Patients with Chronic Total Occlusions: Analysis from the TAXUS ARRIVE Program
| Autor: | Pei-Hsiu Huang, Ruth M. Starzyk, M.P.H. Thomas S. Bowman M.D., David A. Cox, Keith D. Dawkins, Michael Yeung, John M. Lasala |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
biology business.industry Incidence (epidemiology) medicine.medical_treatment Stent medicine.disease biology.organism_classification Surgery Lesion chemistry.chemical_compound Paclitaxel chemistry Taxus medicine Radiology Nuclear Medicine and imaging In patient Myocardial infarction medicine.symptom Cardiology and Cardiovascular Medicine business TIMI |
| Zdroj: | Journal of Interventional Cardiology. 24:232-240 |
| ISSN: | 0896-4327 |
| DOI: | 10.1111/j.1540-8183.2010.00622.x |
| Popis: | Aims: To examine the incidence of clinical events after implantation of the TAXUS Express paclitaxel-eluting stent (PES) in chronic total occlusions (CTO) in an unselected patient population. Methods and Results: The TAXUS ARRIVE registries compiled data on 7,492 patients, including 113 patients with CTO (TIMI flow 0). Patients enrolled at procedure start with no mandated inclusion/exclusion criteria; all cardiac events were monitored with independent end-point adjudication. Two-year follow-up was 89% (101/113) for CTO patients who had significantly more baseline comorbidities/complex disease than simple-use patients undergoing native coronary intervention (N = 2,698) and significantly longer lesions/smaller vessels than other expanded-use patients (N = 4,681 without CTO). Among CTO patients the rate of 2-year major cardiac events (MCE, including cardiac death, myocardial infarction, and target vessel revascularization) was 22.3%, significantly higher than in simple-use patients (10.3%, P < 0.001). CTO MCE was similar to that for other expanded-use patients (16.5%, P = 0.14) but target lesion revascularization was significantly higher in year 2 (6.9% vs. 2.7%, P = 0.02). Academic Research Consortium definite/probable stent thrombosis through 2 years was 5.7%, significantly higher than simple-use patients but similar to other expanded-use cases. Conclusion: In a “real-world” setting, PES use in CTO was associated with increased MCE compared to simple- use patients, but achieved long-term outcomes similar to that observed in other complex patient/lesion cases. (J Interven Cardiol 2011;24:232–240) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|